Nicox outlines next steps for NCX 470 as dust settles on trial results

Shares in Nicox (Euronext Paris: COX) tumbled last week as investors digested the mixed results from its Mont Blanc Phase III trial evaluating NCX 470 in open angle glaucoma or ocular hypertension.

The drug, dubbed a potentially best-in-class, nitric oxide-donating prostaglandin analog eye drop, met the primary objective of non-inferiority in lowering intraocular pressure compared to the standard of care, latanoprost 0.005%, in the 691-patient trial.

In a pre-specified secondary efficacy analysis of time-matched change from baseline IOP, statistical superiority was not achieved, however, explaining the 10% drop in the French company’s share price.